Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview

References

• https://seer.cancer.gov/statfacts ( cited 2021 Jun 13th).
   Google Scholar
• https://ecis.jrc.ec.europa.eu ( cited 2021 Jun 13th).
   Google Scholar
• Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-Part A: renal, Penile, and testicular tumours. Eur Urol. 2016;70(1):93–105. .
   PubMed Web of Science ®Google Scholar
• Trpkov K, Hes O, Williamson SR, et al. New developments in existing WHO entities and evolving molecular concepts: the Genitourinary Pathology Society (GUPS) update on renal neoplasia. Mod Pathol. 2021. Epub ahead of print. DOI:https://doi.org/10.1038/s41379-021-00779-w.
   Google Scholar
• Albiges L, Flippot R, Rioux-Leclerq N, et al. Non-clear cell renal cell carcinomas: from Shadow to light. J Clin Oncol. 2018;36(36):3624–3631. .
   Web of Science ®Google Scholar
• Ciccarese C, Iacovelli R, Brunelli M, et al. Addressing the best treatment for non-clear cell renal cell carcinoma: a meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies. Eur J Cancer. 2017 Sep;83:237–246.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus Everolimus in advanced Renal-Cell carcinoma. N Engl J Med. 2015;373(19):1814–1823. .
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-Cell Carcinoma. N Engl J Med. 2015;373(19):1803–1813. .
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus Sunitinib for advanced renal-Cell.Carcinoma. N Engl J Med. 2019;380(12):1116–1127. .
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced Renal-Cell Carcinoma. N Engl J Med. 2019;380(12):1103–1115. .
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med. 2018;378(14):1277–1290. .
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, et al. CheckMate 9ER Investigators. Nivolumab plus cabozantinib versus sunitinib for advanced Renal-Cell carcinoma. N Engl J Med. 2021;384(9):829–841. .
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Fay AP, Gray KP, et al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178–2184. .
   PubMed Web of Science ®Google Scholar
• Erlmeier F, Weichert W, Schrader AJ, et al. Prognostic impact of PD-1 and its ligands in renal cell carcinoma. Med Oncol. 2017;34(6):99. .
   PubMed Web of Science ®Google Scholar
• Wang Z, Peng S, Xie H, et al. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals. Clin Exp Med. 2018;18(2):165–175. .
   PubMed Web of Science ®Google Scholar
• Raychaudhuri R, Riese MJ, Bylow K, et al. Immune check point inhibition in sarcomatoid renal cell carcinoma: a new treatment paradigm. Clin Genitourin Cancer. 2017;15(5):e897–e901. .
   PubMed Web of Science ®Google Scholar
• Noguchi G, Tsutsumi S, Yasui M, et al. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report. BMC Urol. 2018;18(1):26. .
   PubMedGoogle Scholar
• McDermott DF, Choueiri TK, Motzer RJ, et al. CheckMate 214 post-hoc analysis of nivolumab plus ipilimumab or sunitinib in IMDC intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features. J Clin axitinib. Oncol. 2019;37(15_suppl):4513.
   Web of Science ®Google Scholar
• McGregor BA, McKay RR, Braun DA, et al. Results of a multicenter phase II study of atezolizumab and bevacizumab for patients with metastatic renal cell carcinoma with variant histology and/or sarcomatoid features. J Clin Oncol. 2020;38(1):63–70. .
   PubMed Web of Science ®Google Scholar
• Vogelzang NJ, Olsen MR, McFarlane JJ, et al. Safety and efficacy of nivolumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase IIIb/IV CheckMate 374 study. Clin Genitourin Cancer. 2020;18(6):461–468. .
   PubMed Web of Science ®Google Scholar
• Hsieh JJ. The 2020 nccRCC Immunotherapy Issue. Clin Genitourin Cancer. 2020 Dec;18(6):423–424.
   PubMed Web of Science ®Google Scholar
• Lee CH, Voss MH, Carlo MH, et al. Nivolumab plus Cabozantinib in patients with non-clear cell renal cell carcinoma: results of a phase II trial. JCO. 2021;39(15_suppl):4509. .
   Google Scholar
• Ahrens M, Escudier B, Boleti E, et al. A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST). J Clin Oncol. 2020;38(15_suppl): TPS5103. .
   Web of Science ®Google Scholar
• Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) vancouver classification of renal neoplasia. Am J Surg Pathol. 2013;37(10):1469–1489. .
   PubMed Web of Science ®Google Scholar
• Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490–1504. .
   PubMed Web of Science ®Google Scholar
• Kristiansen G, Delahunt B, Srigley JR, et al. Vancouver-Klassifikation von Nierentumoren: empfehlungen der Konsenskonferenz der Internationalen Gesellschaft für Uropathologie (ISUP) 2012 [vancouver classification of renal tumors: recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)]. Pathologe. 2015;36(3):310–316.
   PubMedGoogle Scholar
• Chevarie-Davis M, Riazalhosseini Y, Arseneault M, et al. The morphologic and immunohistochemical spectrum of papillary renal cell carcinoma: study including 132 cases with pure type 1 and type 2 morphology as well as tumors with overlapping features. Am J Surg Pathol. 2014;38(7):887–894. .
   PubMed Web of Science ®Google Scholar
• Williamson SR, Gill AJ, Argani P, et al. Report From the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer. Am J Surg Pathol. 2020;44(7):e47–e65. .
   PubMed Web of Science ®Google Scholar
• Polifka I, Agaimy A, Herrmann E, et al. High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. Hum Pathol. 2019;83:212–223.
   PubMed Web of Science ®Google Scholar
• Yang C, Shuch B, Kluger H, et al. High WHO/ISUP grade and unfavorable architecture, rather than typing of papillary renal cell carcinoma, may be associated with worse prognosis. Am J Surg Pathol. 2020;44(5):582–593. .
   PubMed Web of Science ®Google Scholar
• Ohashi R, Martignoni G, Hartmann A, et al. Multi-institutional re-evaluation of prognostic factors in chromophobe renal cell carcinoma: proposal of a novel two-tiered grading scheme. Virchows Arch. 2020;476(3):409–418. .
   PubMed Web of Science ®Google Scholar
• Mollica V, Franceschini T, Gruppioni E, et al. Broad spectrum mutational analysis of chromophobe renal cell carcinoma using next-generation sequencing. Pathol Res Pract. 2021 Mar;219:153350. Epub 2021.
   PubMed Web of Science ®Google Scholar
• Halat S, Eble JN, Grignon DJ, et al. Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. Mod Pathol. 2010;23(7):931–936. .
   PubMed Web of Science ®Google Scholar
• Mehra R, Vats P, Cieslik M, et al. Biallelic Alteration and dysregulation of the hippo pathway in mucinous tubular and spindle cell carcinoma of the kiDNEY. Cancer Discov. 2016;6(11):1258–1266. .
   PubMed Web of Science ®Google Scholar
• Gill AJ, Hes O, Papathomas T, et al. Succinate dehydrogenase (SDH)-deficient renal carcinoma: a morphologically distinct entity: a clinicopathologic series of 36 tumors from 27 patients. Am J Surg Pathol. 2014;38(12):1588–1602. .
   PubMed Web of Science ®Google Scholar
• Agaimy A, Cheng L, Egevad L, et al. Rhabdoid and undifferentiated phenotype in renal cell carcinoma: analysis of 32 cases indicating a distinctive common pathway of dedifferentiation frequently associated with SWI/SNF complex deficiency. Am J Surg Pathol. 2017;41(2):253–262. .
   PubMed Web of Science ®Google Scholar
• Cheng JX, Tretiakova M, Gong C, et al. Renal medullary carcinoma: rhabdoid features and the absence of INI1 expression as markers of aggressive behavior. Mod Pathol. 2008;21(6):647–652. .
   PubMed Web of Science ®Google Scholar
• Muller M, Guillaud-Bataille M, Salleron J, et al. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Mod Pathol. 2018;31(6):974–983.
   PubMed Web of Science ®Google Scholar
• Wyvekens N, Valtcheva N, Mischo A, et al. Novel morphological and genetic features of fumarate hydratase deficient renal cell carcinoma in HLRCC syndrome patients with a tailored therapeutic approach. Genes Chromosomes Cancer. 2020;59(11):611–619. .
   PubMed Web of Science ®Google Scholar
• Hakimi AA, Tickoo SK, Jacobsen A, et al. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype. Mod Pathol. 2015;28(6):845–853. .
   PubMed Web of Science ®Google Scholar
• Argani P, Aulmann S, Karanjawala Z, et al. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol. 2009;33(4):609–619. .
   PubMed Web of Science ®Google Scholar
• Wyvekens N, Rechsteiner M, Fritz C, et al. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas. Virchows Arch. 2019;474(5):625–631. .
   PubMed Web of Science ®Google Scholar
• Sukov WR, Hodge JC, Lohse CM, et al. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients. Mod Pathol. 2012;25(11):1516–1525. .
   PubMed Web of Science ®Google Scholar
• Kuroda N, Trpkov K, Gao Y, et al. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217. Mod Pathol. 2020;33(12):2564–2579. .
   PubMed Web of Science ®Google Scholar
• Trpkov K, Hes O, Bonert M, et al. Eosinophilic, solid, and cystic renal cell carcinoma: clinicopathologic study of 16 unique, sporadic neoplasms occurring in women. Am J Surg Pathol. 2016;40(1):60–71. .
   PubMed Web of Science ®Google Scholar
• Trpkov K, Abou-Ouf H, Hes O, et al. Eosinophilic Solid and Cystic Renal Cell Carcinoma (ESC RCC): further morphologic and molecular characterization of ESC RCC as a Distinct Entity. Am J Surg Pathol. 2017;41(10):1299–1308. .
   PubMed Web of Science ®Google Scholar
• Trpkov K, Williamson SR, Gao Y, et al. Low-grade oncocytic tumor of kidney (CD117-negative, cytokeratin 7-positive): a distinct entity? Histopathology. 2019;75(2):174–184. .
   PubMed Web of Science ®Google Scholar
• Ahrens M, Scheich S, Hartmann A, et al. IAG-N Interdisciplinary working group kidney cancer of the German cancer society. non-clear cell renal cell carcinoma - pathology and treatment options. Oncol Res Treat. 2019;42(3):128–135.
   PubMed Web of Science ®Google Scholar
• He H, Trpkov K, Martinek P, et al. “High-grade oncocytic renal tumor”: morphologic, immunohistochemical, and molecular genetic study of 14 cases. Virchows Arch. 2018;473(6):725–738. .
   PubMed Web of Science ®Google Scholar
• Tjota MY, Wanjari P, Segal J, et al. TSC/MTOR mutated eosinophilic renal tumors are a distinct entity that are CK7+/CK20-/vimentin-: a validation study. Hum Pathol. 2020;19:S0046-8177(20)30259–8.
   Google Scholar
• Motzer RJ, Jonasch E, Agarwal N, et al. NCCN Clinical practice guidelines in oncology (NCCN guidelines): kidney cancer version. J Natl Compr Canc Netw 2017, 15:804-834.
   Google Scholar
• Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):706–720. .
   PubMed Web of Science ®Google Scholar
• Bergmann L, Bauernhofer T, Bokemeyer C, et al.Onkopedia Leiltinie: Nierenzellkarzinom (Hypernephrom). 2020.
   Google Scholar
• Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol. 2002;20(9):2376–2381. .
   PubMed Web of Science ®Google Scholar
• Fernández-Pello S, Hofmann F, Tahbaz R, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017;71(3):426–436. .
   PubMed Web of Science ®Google Scholar
• Linehan WM, Srinivasan R, Garcia JA. Non-clear cell renal cancer: disease-based management and opportunities for targeted therapeutic approaches. Semin Oncol. 2013;40(4):511–520.
   PubMed Web of Science ®Google Scholar
• Ravi P, Bakouny Z, Schmidt A, et al. Novel therapeutic approaches and the evolution of drug development in advanced kidney cancer. Cancer J. 2020;26(5):464–470. .
   PubMed Web of Science ®Google Scholar
• Dutcher JP, De SP, McDermott D, et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol. 2009;26(2):202–209. .
   PubMed Web of Science ®Google Scholar
• Escudier B, Molinie V, Bracarda S, et al. Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis. Eur J Cancer. 2016;69:226–235.
   PubMed Web of Science ®Google Scholar
• Buti S, Bersanelli M, Maines F, et al. First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: the Italian retrospective multicenter PANORAMA Study. Clin Genitourin Cancer. 2017;15(4):e609–e614. .
   PubMed Web of Science ®Google Scholar
• Matrana MR, Baiomy A, Campbell M, et al. Outcomes of patients with metastatic Non-Clear-Cell renal cell carcinoma treated with Pazopanib. Clin Genitourin Cancer. 2017;15(2):e205–e208. .
   PubMedGoogle Scholar
• Twardowski PW, Tangen CM, Wu X, et al. Parallel (randomized) Phase II evaluation of Tivantinib (ARQ197) and Tivantinib in combination with Erlotinib in papillary renal cell carcinoma: SWOG S1107. Kidney Cancer. 2017;1(2):123–132. .
   PubMedGoogle Scholar
• Hutson TE, Michaelson MD, Kuzel TM, et al. A phase II study of lenvatinib plus everolimus in patients with advanced non clear cell renal cell carcinoma (nccRCC). J Clin Oncol. 2020;38(6):685.
   Google Scholar
• Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17(3):378–388. .
   PubMed Web of Science ®Google Scholar
• Tannir NM, Jonasch E, Albiges L, et al. Everolimus versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): a randomized multicenter Phase 2 trial. Eur Urol. 2016;69(5):866–874. .
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Barrios CH, Kim TM, et al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J Clin Oncol. 2014;32(25):2765–2772. .
   PubMed Web of Science ®Google Scholar
• Bergmann L, Grünwald V, Maute L, et al. A randomized Phase IIa trial with temsirolimus versus sunitinib in advanced non-clear cell renal cell carcinoma: an intergroup study of the CESAR Central European Society for Anticancer Drug Research-EWIV and the Interdisciplinary Working Group on Renal Cell Cancer (IAGN) of the German cancer society. Oncol Res Treat. 2020;43(7–8):333–339.
   PubMed Web of Science ®Google Scholar
• Bersanelli M, Brunelli M, Gnetti L, et al. Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review. Ther Adv Med Oncol. 2020;12:1758835920915303.
   Web of Science ®Google Scholar
• Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1):127–131. .
   PubMed Web of Science ®Google Scholar
• Koh Y, Lim HY, Ahn JH, et al. Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma. Ann Oncol. 2013;24(4):1026–1031. .
   PubMed Web of Science ®Google Scholar
• Carlo MI, Khan N, Zehir A, et al. Comprehensive genomic analysis of metastatic Non-Clear-Cell renal cell carcinoma to identify therapeutic targets. JCO Precis Oncol. 2019;3: PO.18.00372.
   Web of Science ®Google Scholar
• Dizman N, Philip EJ, Pal SK. Genomic profiling in renal cell carcinoma. Nat Rev Nephrol. 2020;16(8):435–451.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Vaishampayan U, Rosenberg JE, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013;31(2):181–186. .
   PubMed Web of Science ®Google Scholar
• Martínez Chanzá N, Xie W, Asim Bilen M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol. 2019;20(4):581–590. .
   PubMed Web of Science ®Google Scholar
• Pal SK, Tangen C, Thompson JIM, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. .
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Heng DYC, Lee JL, et al. Efficacy of Savolitinib vs Sunitinib in patients with MET-Driven papillary renal cell carcinoma: the SAVOIR phase 3 randomized clinical trial. JAMA Oncol. 2020;6(8):1247–1255. .
   PubMed Web of Science ®Google Scholar
• Suarez Rodriguez C, Larkin J, Patel PM, et al. Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer. JCO. 2021;39(15_suppl):4511.
   Google Scholar
• Motzer RJ, Escudier B, George S, et al. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial. Cancer. 2020;126(18):4156–4167. .
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370–1385. .
   PubMed Web of Science ®Google Scholar
• Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of Nivolumab plus Ipilimumab versus Sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2021;27(1):78–86. .
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha SY, et al. Lenvatinib plus Pembrolizumab or Everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–1300. .
   PubMed Web of Science ®Google Scholar
• Ruiz-Banobre J, Anido U, Abdulkader I, et al. Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: a case report. Front Oncol. 2016;6:250.
   PubMed Web of Science ®Google Scholar
• Adrianzen Herrera DA, Fleisig SB, Gartrell BA. Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: on-label but without evidence. Invest New Drugs. 2017;35(5):665–668.
   PubMed Web of Science ®Google Scholar
• Koshkin VS, Barata PC, Zhang T, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer. 2018;6(1):9. .
   PubMedGoogle Scholar
• Mizutani K, Horie K, Nagai S, et al. Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: a case report. Mol Clin Oncol. 2017;7(6):988–990.
   PubMed Web of Science ®Google Scholar
• Chahoud J, Msaouel P, Campbell MT, et al. Nivolumab for the treatment of patients with metastatic Non-Clear Cell Renal Cell Carcinoma (nccRCC): a Single-Institutional Experience and literature meta-Analysis. Oncologist. 2020;25(3):252–258. .
   PubMed Web of Science ®Google Scholar
• McDermott DF, Lee JL, Ziobro M, et al. Open-Label, Single-Arm, Phase II study of Pembrolizumab monotherapy as First-Line therapy in patients with advanced non-Clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029–1039. .
   PubMed Web of Science ®Google Scholar
• Ahrens M, Scheich S, Hartmann A, et al. Non-clear cell renal cell carcinoma - pathology and treatment options. Oncol Res Treat. 2019;42(3):128–135. .
   PubMed Web of Science ®Google Scholar
• Lebacle C, Pooli A, Bessede T, et al. Epidemiology, biology and treatment of sarcomatoid RCC: current state of the art. World J Urol. 2018;31(1):115–123.
   Google Scholar
• Vera-Badillo FE, Templeton AJ, Duran I, et al. Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis. Eur Urol. 2015;67(4):740–749. .
   PubMed Web of Science ®Google Scholar
• Maiti A, Nemati-Shafaee M, Msaouel P, et al. Phase 2 trial of Capecitabine, Gemcitabine, and Bevacizumab in Sarcomatoid renal-cell carcinoma. Clin Genitourin Cancer. 2017;S1558-7673(17):30238.
   Google Scholar
• Michaelson MD, McKay RR, Werner L, et al. Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor-risk metastatic renal cell carcinoma. Cancer. 2015;121(19):3435–3443.
   PubMed Web of Science ®Google Scholar
• Voss MH, Bastos DA, Karlo CA, et al. Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies. Ann Oncol. 2014;25(3):663–668.
   PubMed Web of Science ®Google Scholar
• Park I, Lee HJ, Bae WK, et al. A multicenter, prospective phase II trial of gemcitabine plus axitinib in patients with renal cell carcinoma with a predominant sarcomatoid component. Invest New Drugs. 2019;37(6):1239–1246.
   PubMed Web of Science ®Google Scholar
• Kawakami F, Sircar K, Rodriguez-Canales J, et al. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation. Cancer. 2017;123(24):4823–4831.
   PubMed Web of Science ®Google Scholar
• Mouallem NE, Smith SC, Paul AK. Sarcomatoid renal cell carcinoma: biology and treatment advances. Urol Oncol. 2018;36(6):265–271.
   PubMed Web of Science ®Google Scholar
• Buonerba C, Dolce P, Iaccarino S, et al. Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in patients with sarcomatoid renal cell carcinoma: a systematic review and meta-Analysis. Cancers (Basel). 2020 Feb 10;12(2):408. PMID: 32050629; PMCID: PMC7072485.
   Web of Science ®Google Scholar
• Geynisman D. Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur Urol. 2015;85(5):912–914.
   Google Scholar
• Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet. 2019;393(10189):2404–2415. .
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Larkin J, Pal S, et al. Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial. ESMO Open. 2021;6(3):100101.
   PubMed Web of Science ®Google Scholar